Xiidra 5% Ophthalmic solution
Lifitegrast eye prep
50mg/ml
Shire Development LLC.
| Pack size | 60 single dose ampules |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 777.50 AED |
Indications
Xiidra 5% Ophthalmic solution is used for:
Dry Eye Disease
Adult Dose
Eye drop
Dry Eye Disease
Indicated for treatment of the signs and symptoms of dry eye disease (DED)
Instill 1 gtt q12hr into each eye
Child Dose
<17 years: Safety and efficacy not established
Renal Dose
Administration
Ophthalmic Administration
Drops are in single-use containers; discard the single-use container immediately after using in each eye
Remove contact lenses before instilling eye drops; may be reinserted 15 minutes following administration
Contra Indications
Precautions
Pregnancy-Lactation
Pregnancy
There are no available data regarding use in pregnant women to inform any drug-associated risks
Animal data (IV administration)
Lifitegrast administered daily by IV injection to rats, from premating through gestation day 17, caused an increase in mean preimplantation loss and an increased incidence of several minor skeletal anomalies at 30 mg/kg/day, representing 5,400-fold the human plasma exposure at the recommended human ophthalmic dose (RHOD)
In rabbits, an increased incidence of omphalocele was observed at the lowest dose tested, 3 mg/kg/day (400-fold the human plasma exposure at the RHOD, based on AUC), when administered by IV injection daily from gestation days 7 through 19
Lactation
There are no data on the presence of lifitegrast in human milk; systemic exposure to lifitegrast from ocular administration is low
Interactions
Adverse Effects
Side effects of Lifitegrast eye prep :
>10%
Instillation site irritation (5-25%)
Dysgeusia (5-25%)
Reduced visual acuity (5-25%)
1-10%
Blurred vision (1-5%)
Conjunctival hyperemia (1-5%)
Eye irritation (1-5%)
Headache (1-5%)
Increased lacrimation (1-5%)
Eye discharge (1-5%)
Eye discomfort (1-5%)
Eye pruritus (1-5%)
Sinusitis (1-5%)
Mechanism of Action
The exact mechanism in dry eye disease is not known
Binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein bound on leukocytes, and blocks the interactions of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1)
ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease; LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues
In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells
Note
Xiidra 5% 50mg/ml Ophthalmic solution manufactured by Shire Development LLC. . Its generic name is Lifitegrast eye prep. Xiidra 5% is availble in United Arab Emirates.
Farmaco UAE drug index information on Xiidra 5% Ophthalmic solution is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.